BLACKWOOD, N.J.–(BUSINESS WIRE)–Refac Holdings, Inc. announces the completion of its acquisition by Lincoln Road Advisors, Inc.
Author: Business Wire
Azura Ophthalmics Announces Positive Topline Results From Phase 2 Program of the Company’s Investigational Treatment for Meibomian Gland Dysfunction
TEL AVIV, Israel & MELBOURNE, Australia–(BUSINESS WIRE)–Azura Ophthalmics today announced topline results from a phase 2a program evaluating the company’s investigational therapy for the treatment of MGD.
Beverly Capital Invests in The Eye Health Group
LOS ANGELES–(BUSINESS WIRE)–Beverly Capital, a Los Angeles-based private equity firm, announced today that it has acquired The Eye Health Group, a New Jersey-based medical optometric service provider. The Eye Health Group is a leading vision support …
Iveric Bio Reports Fourth Quarter and Year End 2020 Operational Highlights and Financial Results
NEW YORK–(BUSINESS WIRE)–Iveric Bio announced financial and operating results for the fourth quarter and full year ended Dec. 31, 2020 and provided a general business update.
National Vision Holdings, Inc. Reports Fourth Quarter and Fiscal 2020 Financial Results
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) today reported its financial results for the fourth quarter and fiscal year ended January 2, 2021 and is providing its outlook for fiscal 20…
Global Spectacle Market (2020 to 2026) – by Parts, Distribution Channel and Region – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Spectacle Market By Parts (Lens and Frames), By Distribution Channel (Online and Offline), By Region, Industry Analysis and Forecast, 2020 – 2026” report has been added to ResearchAndMarkets.com’s offering. The Glob…
Craig Lipset is Appointed Chairman of the Trialbee Industry Advisory Board
RESEARCH TRIANGLE PARK, N.C. & MALMÖ, Sweden–(BUSINESS WIRE)–Craig is the former Head of Clinical Innovation and Venture Partner at Pfizer
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK–(BUSINESS WIRE)–Iveric Bio granted non-statutory stock options to purchase an aggregate of 41,500 shares of common stock to 2 newly hired, non-executive employees.
Kala Pharmaceuticals to Present at Upcoming Investor Conferences in March
WATERTOWN, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that management will p…
Eyenovia Announces FDA Acceptance of the MydCombi NDA
NEW YORK–(BUSINESS WIRE)– #mydriasis–FDA accepts Eyenovia’s NDA for MydCombi, a unique fixed combination pupil dilation agent delivered with the Optejet. PDUFA date is expected 4Q 2021.
Glaukos Announces Participation in Oppenheimer Healthcare Conference
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that …
Glaukos Appoints Denice Torres and Dr. Leana Wen to its Board of Directors
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the a…
Alcon’s Sue-Jean Lin Wins 2021 Dallas CIO of the Year
FORT WORTH, Texas–(BUSINESS WIRE)–Alcon’s Sue-Jean Lin Wins 2021 Dallas CIO of the Year
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Business Update on March 11, 2021
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #AMD–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report i…
Ocular Therapeutix™ Announces First Patient Dosed in Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today…
Gyroscope Therapeutics Appoints Jessica Stitt as Chief Financial Officer
LONDON–(BUSINESS WIRE)–Gyroscope Therapeutics Appoints Jessica Stitt as Chief Financial Officer.
Pharmaron Acquires State-of-the-Art Biomanufacturing Site in the United Kingdom from AbbVie
BEIJING–(BUSINESS WIRE)– #biomanufaturing–Pharmaron Acquires State-of-the-Art Biomanufacturing Site in the United Kingdom from AbbVie
武田提供Novavax和Moderna的COVID-19候選疫苗在日本的1/2期臨床試驗的最新資訊
日本大阪–(BUSINESS WIRE)–(美國商業資訊)–武田藥品工業株式會社(TSE:4502/NYSE:TAK)今天宣布，Novavax的COVID-19候選疫苗(TAK-019)在日本的1/2期免疫原性和安全性研究完成首例受試者接種。本月稍早，武田完成了Moderna的COVID-19候選疫苗(TAK-919)在日本的1/2期免疫原性和安全性研究入組。 武田全球疫苗業務部總裁Rajeev Venkayya, M.D.表示：「在大流行初期，我們決定與其他公司合作，發揮我們豐富的疫苗經驗和…
武田提供Novavax和Moderna的COVID-19候选疫苗在日本的1/2期临床试验的最新信息
日本大阪–(BUSINESS WIRE)–(美国商业资讯)–武田药品工业株式会社(TSE:4502/NYSE:TAK)今天宣布，Novavax的COVID-19候选疫苗(TAK-019)在日本的1/2期免疫原性和安全性研究完成首例受试者接种。本月早些时候，武田完成了Moderna的COVID-19候选疫苗(TAK-919)在日本的1/2期免疫原性和安全性研究入组。 武田全球疫苗业务部总裁Rajeev Venkayya, M.D.表示：“在大流行初期，我们决定与其他公司合作，发挥我们丰富的疫苗经…
Glaukos Corporation Announces Fourth Quarter and Full Year 2020 Financial Results
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced finan…